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Abstract Activating mutations of the TSH receptor gene have 
been found in toxic adenomas and hereditary toxic thyroid 
hyperplasia. Up to now, all mutations have been located in the 
serpentine portion of the receptor. We now describe two 
additional mutations affecting Ser-281 (Ser-281-Thr and Ser-
281-Asn) in the ectodomain of the receptor. After transfection in 
COS cells, both mutants displayed increased constitutive activity 
for cAMP generation despite expression at a lower level than the 
wild type. The mutants were responsive to TSH. The present 
results are compatible with a model in which the activity of the 
unliganded receptor is kept at a low level by an inhibitory 
interaction between the N-terminal domain and the serpentine 
portion of the receptor. 
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1. Introduction 
G protein-coupled receptors (GPCRs) belonging to the op-
sin subgroup constitute the largest family of membrane recep-
tors, with more than 500 members expected [1,2]. Their se-
quence similarity and probable common evolutionary origin 
suggest that these receptors share common mechanisms of 
action. According to a current model for G P C R activation, 
the receptor would exist under at least two interconverting 
conformations: R (silent conformation) and R* (the active 
form). Binding of the ligand, to the slit between the trans-
membrane segments (for biogenic amines) [1] and/or res-
idues of the N-terminal segment or extracellular loops (for 
neuropeptides) [3], is believed to stabilize the R* confor-
mation [4]. The resulting change in the relative position 
of t ransmembrane helices translates into conformational 
changes of the cytoplasmic domains interacting with G pro-
teins. 
A variety of amino-acid substitutions at different positions 
of G P C R can lead to their constitutive activation [5-7] : the 
silent form of the receptors (R) would be submitted to a 
structural constraint which could be released by a number 
of different mutat ions [4,5]. The thyrotropin receptor is an 
interesting G P C R in this respect: (1) with the other glycopro-
tein hormone receptors (LH/CGr and FSHr) , it is character-
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ized by a structural and functional dichotomy between ligand 
binding, to the long N-terminal domain typical of these re-
ceptors, and activation of G s , by the serpentine port ion; (2) 
the wild-type receptor displays readily measurable constitutive 
activity upon transfection in COS cells [8,9]; and (3) amino-
acid substitutions at as many as 19 different residues of the 
receptor increase its constitutive activity ([9-11], present and 
submitted data). 
All spontaneous activating mutat ions have been found in 
the serpentine portion of the receptor encoded by exon 10 
[9,10,12,13]. Analysis of the functional characteristics of a 
series of constitutively active TSH receptor mutants [13] and 
the observation that low concentration of trypsin activates the 
receptor [14] led us to hypothesize that the unliganded N -
terminal extracellular domain might contribute in keeping 
the serpentine portion of the receptor in the inactive (R) con-
formation. If correct, this model predicts the existence of ac-
tivating mutations, not only in the exoloops of the serpentine 
domain (where they have been found [13]) but also in the N -
terminal domain. In both cases, destruction of the interaction 
or emergence of new repulsive interactions between the extra-
cellular and the serpentine domains would result in receptor 
activation. 
2. Materials and methods 
2.1. PCR, sequence and cloning 
DNA was extracted from nodular tissue, juxtanodular quiescent 
tissue and peripheral blood leukocytes. PCR for exons 1-9 were per-
formed using intronic primers [15] as described. PCR products were 
sequenced on both strands. After cloning, constructs were verified by 
sequencing on both strands. 
2.2. Transfection and functional tests 
COS-7 cells were used for transient expression allowing functional 
assays. They were transfected by the DEAE-dextran method followed 
by a dimethylsulfoxide shock [16]. 
Two days after transfection, cells were used for flow immuno-cyto-
fluorometry, cAMP or inositol phosphate determinations and 125I-
TSH-binding studies. Triplicate dishes were used for each assay. 
Each experiment was repeated at least twice. Ser-281-Asn and Ser-
281 -Thr constructs were compared with the wild-type receptor. Cells 
transfected with pSVL alone were always run as controls. 
(1) cAMP determination, inositol phosphate determination and 
binding assays were performed as previously described [17-20]. 
(2) Flow immuno-cytofluorometry : cells were prepared as described 
[14]. They were incubated with PBS-BSA 0.1% containing either the 
2C11 monoclonal antibody (10 ug/ml) against TSHr, kindly provided 
by Dr. A.P. Johnstone [21], or a new monoclonal antibody, BA8, 
obtained from genetic immunization with the wild-type TSH receptor 
cDNA (S. Costagliola et al., to be published). 2C11 recognizes a linear 
epitope (354-359; VFFEEQ) [14] whereas BA8 recognizes only the 
native receptor as expressed at the surface of cells (S. Costagliola, to 
be published). 
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2.3. Computation of transfection efficiency and specific constitutive 
activity 
Fold constitutivity above COS cells was determined for each con-
struct using the following formula: 
{Ce = [An-Z(l-e)] /Ze} 
where An is the basal cAMP value as experimentally measured, Z is 
the basal cAMP value for mock-transfected cells (pSVL) and e is the 
transfection efficiency defined as the fraction of cells having taken and 
amplified the pSVL-based constructs, e was measured, with identical 
results, from FACS analyses using the wild-type TSH receptor con-
struct and the 2C11 or BA8 monoclonal antibodies, or pSVL con-
structs harboring the green fluorescent protein. Transfection efficiency 
was consistent within a given experiment but varied significantly be-
tween different experiments. In preliminary experiments, it was 
checked that cAMP levels in untransfected COS-7 cells were not dif-
ferent from those in cells transfected with the empty vector. Ce is thus 
the ratio between the cAMP level in cells expressing the receptor 
constructs, over the 'house-keeping' cAMP in the same number of 
cells transfected with the empty pSVL vector. {Ce/Re} normalizes 
Ce for the level of expression of each construct (see below). A measure 
of the relative constitutivity of the mutant receptor over the wild type 
is given by {F = Ce mutant/Ce wild type}. This value does not account 
for the differences in expression of the mutants at the cell surface. It 
gives a measure of relative constitutivity at the actual level of expres-
sion achieved by individual receptor mutants. An estimation of 'spe-
cific constitutivity' (i.e. constitutivity normalized to equal level of ex-
pression) is given by {SCA = F/Re} where Re is a measure of the 
expression of the mutant receptors relative to the wild type with 
{Re = (Mut-pSVL)/(WT-pSVL)}, the ratio between the fluorescence 
(expressed in arbitrary units) of cells transfected with the mutant 
receptors (Mut) and the wild type (WT), after subtraction of the 
background fluorescence displayed by mock-transfected cells 
(pSVL). The comparison of SCA calculated for each construct deter-
mines the fold increase in constitutivity of each mutant over the wild 
type if their levels of expression were identical. In more recent experi-
ments, Re was determined with both 2C11 and BA8 monoclonal anti-
bodies: the results were identical. 
2.4. Statistics 
The level of significance of the differences observed between the 
various constructs was evaluated by a two-tailed Student's 7-test, 
two-tailed Wilcoxon's test or two-tailed Mann-Whitney's test as in-
dicated in the text and in the legends to figures. P < 0.05 was consid-
ered significant. 
3. Results 
We analyzed exons 1-9 of the TSH receptor gene from a 
series of 9 autonomous nodules for which no mutation had 
been found in the serpentine portion of the receptor encoded 
by exon 10 or in G sa. Exons 1-9 were amplified by PCR on 
DNA extracted from individual adenomas, adjacent tissue 
and peripheral white blood cells. Direct sequencing of the 
PCR products on both strands identified two different muta-
tions affecting the same Ser-281 residue in three adenomas: 
substitution of asparagine for serine (AGC->AAC; Ser-281 -
Asn) in one nodule (Fig. la) and threonine for serine (AGC-
->ACC; Ser-281-Thr) in two others (Fig. lb). In the three 
cases, the mutations were in the heterozygous state and con-
fined to the adenoma. Direct sequencing indicated a ratio of 
the mutant vs. the wild-type allele of < 1 (Fig. la,b) suggest-
ing that the nodular tissues were heterogenous or contami-
nated by normal cells harboring the WT genotype (fibroblasts, 
endothelial cells, blood cells, etc.). 
The functional characteristics of the Mut receptors were 
studied by transient expression in COS cells. The WT receptor 
and the empty pSVL vector were used as controls. Levels of 
expression at the cell surface were evaluated by flow cytom-
etry using two monoclonal antibodies recognizing different 
Fig. 1. Sequencing results : Direct sequencing of PCR products from 
a nodule shows a G to A transition leading to a substitution of as-
paragine for serine at position 281 (AGC->AAC) (a). In two differ-
ent nodules, a G to C transversion led to a substitution of threonine 
for serine at the same position (AGC-»ACC) (b). Sequencing was 
performed on both strands. Coding strands are shown for quiescent 
tissue harboring the normal allele (panel N) and for a nodule har-
boring the mutated allele (panel M). 
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Fig. 2. Expression of the Mut receptors: Analysis by flow cytometry of the expression of the mutants. Graphics show the fluorescence intensity 
expressed in arbitrary units (log scale, abscissa) vs. cell number (in ordinates) (see Section 2). Panel A, the 2C11 monoclonal antibody was 
used; Al , mock-transfected cells (pSVL alone); A2, cells transfected with the WT receptor construct; A3, cells transfected with the Mut recep-
tor Ser-281-Thr; A4, cells transfected with the Mut receptor Ser-281-Asn. Panels Bl-4, same as A1-4, except that the BA8 monoclonal anti-
body was used. The mean fluorescence (mean) of the cells and the level of Mut receptor expression relative to the wild type (Re, see Section 2) 
are indicated. 
Table 1 
Characteristics of the Ser-281-Thr and Ser-281-Asn mutants 
Expt. cAMP base (pm/dish) 
WT TSHr 1 
2 
3 
4 
5 
6 
7 
8 
S281T 1 
2 
3 
4 
5 
6 
7 
8 
S281N 1 
2 
3 
4 
5 
6 
7 
8 
6.60 ±0.90 
22.30 ±2.30 
9.75± 1.10 
18.70±2.10 
5.90 ±0.20 
8.84 ±3.60 
69.47 ± 7.95 
22.29 ±1.48 
17.80 ±3.90 
53.70 ±9.00 
24.15 ±7.30 
56.60 ±1.90 
19.25 ±0.20 
30.90 ±3.90 
141.90 ±14.55 
97.62 ±6.07 
*P = 0.0078 
22.20 ±4.20 
44.20 ±7.50 
23.90 
46.00 ±3.30 
19.70±0.14 
39.60 ±1.00 
188.5±0.71 
125.63 ±2.27 
*P = 0.0078 
Ce Re Ce/Re SCA 
15.60 
75.60 
16.80 
46.30 
31.40 
20.70 
13.73 
5.54 
45.90 
187.80 
46.60 
151.60 
107.25 
79.00 
28.49 
19.46 
*P = 0.0078 
57.80 
153.80 
47.40 
122.10 
109.80 
102.00 
37.99 
25.17 
*P = 0.0078 
**P=1 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
2.94 
2.48 
2.77 
3.27 
3.42 
3.82 
2.07 
3.50 
3.03 ±0.58 
3.71 
2.03 
2.82 
2.64 
3.50 
4.93 
2.77 
4.50 
3.36 ±0.99 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
0.71 
0.90 
0.46 
0.64 
0.29 
0.53 
0.63 
0.72 
1.12 
0.60 
0.66 
0.55 
0.43 
0.51 
0.50 
0.50 
15.60 
75.60 
16.80 
46.30 
31.40 
20.70 
13.73 
5.54 
64.65 
208.67 
101.30 
236.88 
369.83 
149.06 
45.22 
27.03 
°P = 0.0047 
51.61 
256.33 
71.82 
222.00 
255.35 
200.00 
75.98 
50.34 
°P = 0.0011 
°°P = 0.7984 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
1.00 
4.06 
2.75 
6.08 
5.10 
11.56 
7.14 
3.29 
4.88 
5.61 ±2.79 
3.30 
3.30 
4.20 
4.80 
8.05 
9.50 
5.53 
9.08 
5.97 ±2.55 
See Section 2 for the definition and computation of the Ce, F,Re and SCA parameters. Results from 8 independent experiments performed in 
triplicate are shown. According to this parameter, Ser-281-Thr and Ser-281-Asn mutants are 6.10 ±3.10- and 5.50 ± 2.60-fold more constitutive than 
the WT receptor, respectively. The differences between the mutants and the wild type were significant (* and °P values) but the values obtained for 
the two mutants were not significantly different from each other (** and °°P values) ('two-tailed Wilcoxon's test, "two-tailed Mann-Whitney's test). 
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epitopes in the extracellular domain of the receptor [14,21] 
(see Section 2) (Fig. 2). Results indicate a slightly lower 
expression for both mutants (Fig. 2, Table 1). Although the 
mutations affect the extracellular domain, the apparent affin-
ity of the mutant for bovine TSH was not decreased. On the 
contrary, and as previously observed for other TSHr mutants 
[9], the Mut receptors had a lower apparent dissociation 
constant (Äj) as compared to wild type: the K& values for 
wild type, Ser-281-Thr and Ser-281-Asn mutants were 
1.24 ±0.71, *0.58±0.1 and **0.49±0.11 mU/ml, respectively 
(meantS.D., M = 4). The difference between the Kd of the 
mutants and the K^ of the wild type was significant 
(*p = **p = 0.0286) although the difference between the mu-
tants was not (P = 0.2) (two-tailed Mann-Whitney's test). 
Fig. 4. IP determination: Mut receptors (Ser-281-Asn, Ser-281-Thr), 
WT receptor (wt TSHr) and pSVL alone were transfected in COS 
cells (150000 cells/dish). Accumulation of IP was determined under 
basal conditions (white columns), stimulation by TSH 100 mU/ml 
(crossed columns) or ATP 100 uM (gray columns). Results are ex-
pressed as the percentage of radioactivity incorporated in inositol-
phosphates over the sum of radioactivity in inositolphosphates and 
phosphatidylinositols ([IPl+IP2+IP3]/[IP+Pi])X 100. Values are 
mean ± S.D. from a representative experiment out of two where de-
termination was performed in triplicate. The differences between the 
mutants and the wild type were not significant: *P= 1; °P = 0.6681; 
" P = 0.5292; °°P = 0.1913 (unpaired two-tailed Student's f-test). 
Fig. 3. cAMP determination: (a) Mut receptors (Ser-281-Asn and 
Ser-281-Thr), WT receptor (wt TSHr) and pSVL alone were trans-
fected in COS cells (150000 cells/dish). Accumulation of cAMP was 
determined under basal conditions (white columns), stimulation by 
TSH 100 mU/ml (crossed columns) or forskolin 10 uM (gray col-
umns). Values are mean ± S.D. from a representative experiment out 
of 6 where determination was performed in triplicate. The signifi-
cance of the differences between the mutants and the wild type was 
etablished after performing an unpaired two-tailed Student's f-test: 
*/> = 0.0084; °P = 0.0033; " P = 0.7073; ooP = 0.6735. The difference 
between the basal values of the two mutants was not significant 
(P = 0.2544). (b) Accumulation of cAMP was determined after stim-
ulation of transfected cells by various TSH concentrations. The dif-
ference between the EC50 values obtained for the three constructs 
was not significant: 0.2 mU/ml for wt TSHr, 0.39 mU/ml for Ser-
281-Thr OP = 0.9746) and 0.24 mU/ml for Ser-281-Asn (P = 0.3703) 
(unpaired two-tailed Student's f-test). 
Cells transfected with the Mut receptors display a higher 
basal cAMP level than those transfected with the wild type 
(Fig. 3a). As described previously [17,22], there is synergism 
between stimulation by forskolin and the constitutive activity 
of the receptors (Fig. 3a). The data from flow immuno-cyto-
fluorometry allow measurement of efficiency of transfection 
and computation of the increase in cAMP within the effec-
tively transfected cells (see Section 2). It demonstrates a 
3.03 ±0.58- and 3.36 ± 0.99-fold increase in cAMP in cells 
transfected with the Ser-281-Thr and Ser-281-Asn Mut con-
structs over cells transfected with the WT construct, respec-
tively (Table 1). Assuming that the mutations do not affect 
recognition by the monoclonal antibodies, these data allow 
also normalization of the increase in cAMP accumulation to 
the amount of receptor expressed at the cell surface, yielding 
an estimation of 'specific constitutive activity' (see Section 2) : 
the Ser-281-Thr and Ser-281-Asn mutants were 5.61 ±2.79 
and 5.97 ±2.55 more active than the wild type, respectively 
(Table 1). 
When stimulated by TSH (Fig. 3b), the WT and Mut re-
ceptors displayed similar EC50 ( = 0.2 mU/ml) and maximally 
active TSH concentration ( = 1 0 mU/ml) for cAMP genera-
tion. 
Basal inositol phosphate accumulation was identical in COS 
cells transfected with both Mut or WT receptor constructs. 
Under stimulation by 100 mU/ml TSH, the response was the 
same for the three constructs (Fig. 4). 
4. Discussion 
Mutations leading to an increase in the constitutive activity 
of the TSH receptor have been described in the second, third, 
sixth and seventh transmembrane segments, in the first and 
second exoloops and in the third cytoplasmic loop 
[9,10,13,17,18,23-31]. The majority of these Mut receptors 
share similar functional characteristics. The interest of the 
two new mutants described here, Ser-281-Thr and Ser-281-
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Fig. 5. Model for receptor activation: The model postulates that two forms of the unliganded TSH receptor co-exist: the 'closed' or inactive 
conformation (A), stabilized by putative interactions between the extracellular and the serpentine domains and the 'open' or active conforma-
tion where these interactions are released (B). Activation by TSH would result from the stabilization of the 'open' conformation (C). 
Asn, resides more in the location of the Mut residue than in 
their functional characteristics which do not deviate from the 
general pattern. 
Ser-281 is conserved in the extracellular domain of glyco-
protein hormone receptors [28], downstream from the leucine-
rich domain for which a structural model has been proposed 
recently [29]. Site-directed mutagenesis and chimeras studies 
have been performed to probe the structure-function relation-
ships of the extracellular domain of the TSH receptor ([6,8,28] 
and references therein) Ser-281 belongs to a segment (amino 
acids 171 418) proposed to play a role in signal transduction 
[30]. Residues 270-278 and 287-297 would be particularly 
important in this regard [31] but the various constructs were 
not explored for their constitutive activity. 
A currently favored model for GPCR activation holds it 
that a structural constraint is responsible for the maintenance 
of unliganded receptors in the inactive state [4]. This model 
was elaborated from the observation that a variety of amino-
acid substitutions, first in the third intracytoplasmic loop of 
adrenergic receptors [32], then in transmembrane helices of 
others [33] could activate them in the absence of agonists. 
Whereas it is relatively easy to understand how binding of 
norepinephrine between transmembrane helices would stabi-
lize the active conformation of adrenergic receptors, it is dif-
ficult to envision how binding of the bulky TSH to the N-
terminal domain would result in the activation of the serpen-
tine portion of the receptor. 
A series of experimental observations led us to hypothesize 
that the extracellular domain of the TSH receptor could con-
tribute in keeping its serpentine portion inactive: (1) amino-
acid substitutions in the first (Ile-486) and second extracellular 
loops (Ile-568) are amongst the strongest activating mutations 
identified [13]; (2) the TSH receptor can be activated by a 
limited proteolytic treatment by trypsin which removes an 
epitope (residues 354-359) of the extracellular domain [14]; 
and (3) the group of Kosugi has demonstrated significant 
increase in constitutive activity of a deleted mutant lacking 
residues 339-367 [34]. These observations are compatible 
with a model in which the unliganded inactive conformation 
of the receptor would be stabilized by interactions between the 
extracellular N-terminus and the extracellular loops. Rupture 
of these interactions would activate the serpentine portion 
while increasing the affinity of the extracellular domain for 
TSH binding. The replacement of Ser-281 with two different 
amino acids (Asn or Thr), increasing the constitutive activity 
of the receptor, fits well with such a model. The recent iden-
tification of an additional and more drastic amino-acid sub-
stitution at the same residue (Ser-281-He) strengthen this view 
(P. Kopp and L. Jameson, personal communication). 
According to the model, unliganded receptors would exist 
as an equilibrium between a 'closed' inactive conformation 
and an 'open' active conformation lacking the interaction be-
tween the loops and the N-terminal domain (Fig. 5). The 
concentration of the latter would be responsible for the con-
stitutive activity of the WT receptor. Binding of TSH to the 
extracellular domain would activate the receptor by stabilizing 
the 'open' conformation. The model does not exclude that an 
interaction of TSH with the extracellular loops contributes to 
the stabilization of the active conformation of the serpentine 
portion as suggested by some experiments with the LH/CG 
receptor [35-38]. A model for activation of the LH/CG recep-
tor is based on similar prémices [39]. 
Our model is compatible with many experimental observa-
tions but not with all: (1) the expression of the serpentine 
domain alone should cause constitutive adenylyl-cyclase stim-
ulation in transfected cells. This was apparently not the case 
in a widely quoted experiment performed with the LH/CG 
receptor [38]. For the TSH receptor, there has been no con-
vincing report of expression at the cell surface of such trun-
cated forms; (2) if stabilization of the 'open' conformation 
would automatically activate the receptor, all TSH binding 
molecular species should always be agonists. However, degly-
cosylated forms of TSH can loose their agonist properties 
while still capable of binding efficiently [40^12]. It is conceiv-
able, as suggested for the LH/CG receptor [39], that the car-
bohydrate moiety of TSH contributes to the steric hindrance 
that follows the binding of the hormone and leads to stabili-
zation of the activated conformation of the receptor. The 
'open-closed' model is certainly a gross oversimplification of 
reality. We believe, nevertheless, that it has euristic value as it 
provides an explanation for the activation of the receptor by 
its normal agonist, by partial proteolysis and suggests an ap-
pealing explanation for the activation by autoantibodies in 
Graves' disease. Similarly, and as evidenced by recent experi-
ments [43], the effects of experimental antibodies with block-
ing activity (TSBab) could be to stabilize the silent, 'closed' 
conformation of the receptor thus behaving as inverse ago-
nists. 
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